ATE508108T1 - Neue verbindungen, verfahren zu deren herstellung und deren verwendung - Google Patents

Neue verbindungen, verfahren zu deren herstellung und deren verwendung

Info

Publication number
ATE508108T1
ATE508108T1 AT08712766T AT08712766T ATE508108T1 AT E508108 T1 ATE508108 T1 AT E508108T1 AT 08712766 T AT08712766 T AT 08712766T AT 08712766 T AT08712766 T AT 08712766T AT E508108 T1 ATE508108 T1 AT E508108T1
Authority
AT
Austria
Prior art keywords
compounds
bound
ring
methods
oxygen atom
Prior art date
Application number
AT08712766T
Other languages
English (en)
Inventor
Andersson Helen Tuvesson
Ulf Vellmar
Ingrid Hallin
Leif Svensson
Ingela Fritzson
Original Assignee
Chelsea Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chelsea Therapeutics Inc filed Critical Chelsea Therapeutics Inc
Application granted granted Critical
Publication of ATE508108T1 publication Critical patent/ATE508108T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT08712766T 2007-02-06 2008-01-31 Neue verbindungen, verfahren zu deren herstellung und deren verwendung ATE508108T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89966007P 2007-02-06 2007-02-06
SE0700281 2007-02-06
PCT/SE2008/050126 WO2008097180A1 (en) 2007-02-06 2008-01-31 New compounds, methods for their preparation and use thereof

Publications (1)

Publication Number Publication Date
ATE508108T1 true ATE508108T1 (de) 2011-05-15

Family

ID=39410346

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08712766T ATE508108T1 (de) 2007-02-06 2008-01-31 Neue verbindungen, verfahren zu deren herstellung und deren verwendung

Country Status (11)

Country Link
US (2) US8263658B2 (de)
EP (1) EP2118051B1 (de)
JP (1) JP5349332B2 (de)
KR (1) KR20090110931A (de)
AT (1) ATE508108T1 (de)
AU (1) AU2008213147A1 (de)
CA (1) CA2677457A1 (de)
DE (1) DE602008006679D1 (de)
ES (1) ES2366000T3 (de)
NZ (1) NZ579040A (de)
WO (1) WO2008097180A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2135610A1 (de) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Kombination mit DHODH-Inhibitoren und Methotrexat
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2239256A1 (de) 2009-03-13 2010-10-13 Almirall, S.A. Natriumsalz von 5-cyclopropyl-2-{[2-(2,6-difluorphenyl)pyrimidin-5-yl]amino}benzoesäure als DHODH-Inhibitor
EP2314577A1 (de) 2009-10-16 2011-04-27 Almirall, S.A. Verfahren zur Herstellung von 2-[(3,5-Difluor-3'-methoxy-1,1'-biphenyl-4-yl)amino]nikotinsäure
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2672963A4 (de) 2011-02-08 2015-06-24 Childrens Medical Center Verfahren zur behandlung von melanomen
WO2013088299A1 (en) * 2011-12-13 2013-06-20 Koninklijke Philips Electronics N.V. Optical collimator for led lights
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
US10692863B2 (en) * 2016-09-30 2020-06-23 Rohm Co., Ltd. Semiconductor device and semiconductor package
JP7205830B2 (ja) 2017-08-07 2023-01-17 国立大学法人広島大学 新規アントラニル酸系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2064305A1 (en) 1970-12-29 1972-07-06 Farbenfabriken Bayer Ag, 5090 Leverkusen Anthranilic acid esters alkylated on the nucleus
US4307113A (en) 1978-04-20 1981-12-22 Sandoz, Inc. Anthranilic acid derivatives
EP0034292B1 (de) 1980-02-06 1983-11-23 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Verfahren zur Herstellung von Anthranilsäurederivaten
NO174506B (no) 1984-10-30 1994-02-07 Usv Pharma Corp Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser
HUT60458A (en) * 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
HUP9801828A3 (en) * 1995-03-14 2001-02-28 Novartis Ag Benzoic acid, quinoline and quinazoline derivatives, pharmaceutical compositions containing them and process for producing them
WO1997028118A1 (en) 1996-02-05 1997-08-07 Hoechst Celanese Corporation Process for preparing anthranilic acids
AU3376699A (en) * 1998-03-31 1999-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
DE10254872A1 (de) 2002-11-25 2004-06-03 Symrise Gmbh & Co. Kg Anthranilsäureamide und deren Derivate als kosmetische und pharmazeutische Wirkstoffe
SE0400234D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New compounds, methods for their preparation and use thereof

Also Published As

Publication number Publication date
US20100029767A1 (en) 2010-02-04
EP2118051B1 (de) 2011-05-04
JP2010520857A (ja) 2010-06-17
ES2366000T3 (es) 2011-10-14
JP5349332B2 (ja) 2013-11-20
EP2118051A1 (de) 2009-11-18
KR20090110931A (ko) 2009-10-23
AU2008213147A1 (en) 2008-08-14
DE602008006679D1 (de) 2011-06-16
US20120283326A1 (en) 2012-11-08
WO2008097180A1 (en) 2008-08-14
NZ579040A (en) 2011-01-28
US8461205B2 (en) 2013-06-11
CA2677457A1 (en) 2008-08-14
US8263658B2 (en) 2012-09-11

Similar Documents

Publication Publication Date Title
DE602008006679D1 (de) Neue verbindungen, verfahren zu deren herstellung und deren verwendung
PH12012501535A1 (en) Substituted naphthyridines and their use as syk kinase inhibitors
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
NZ597994A (en) Nitrogen-containing spiro-ring compound and medicinal use of same
WO2008115098A3 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
MX2010004893A (es) Compuesto heterociclico y composicion farmaceutica del mismo.
AR078833A1 (es) Derivados de heteroarilos que contienen nitrogeno como inhibidores dela cinasa jak3
MX2009003882A (es) Compuestos heteroaromaticos biciclicos.
ATE515505T1 (de) Heterocyclische fxr-bindende verbindungen
NI201000124A (es) Derivados de carboxamidas azabicíclicas, su preparación y su aplicación en terapéutica
MX2009010909A (es) Derivados de ftalazino y su uso como medicamento para tratar el cancer.
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
NO20092689L (no) Quinuclidinolderivater som muskarin reseptorantagonister
MX2012002641A (es) Inhibidores de cinasa janus (jak).
AR074558A1 (es) Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3
TW200745034A (en) New compounds
ATE400547T1 (de) Anthranilsäurederivate, verfahren zu deren herstellung und deren verwendung als dhodh inhibitoren
PH12012500867A1 (en) Ethynyl derivatives
JO2808B1 (en) Compounds and their preparation and pharmaceutical compounds
PE20141168A1 (es) Derivados de pirazolidin-3-ona
RU2012146325A (ru) Терапевтическое средство или профилактическое средство для лечения фибромиалгии
MX2011012068A (es) Nucleosidos 2'-fluoro arabino y su utilizaicon.
MX2009013775A (es) Sustituto novedoso de piperidones sustituidas como inductor de hsp.
WO2009025265A1 (ja) ピペラジン誘導体
MX2011009746A (es) Derivados de n-[(6-aza-biciclo[3.2.1]oct-5-il)-abril-metil]-hetero benzamida, su prepracion y su uso en terapeutica.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties